TY - JOUR
T1 - A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
AU - Uemura, Marc
AU - Faisal, Faa'k
AU - Haymaker, Cara
AU - McQuail, Natalie
AU - Sirmans, Elizabeth
AU - Hudgens, Courtney W.
AU - Barbara, Lydia
AU - Bernatchez, Chantale
AU - Curry, Jonathan L.
AU - Hwu, Patrick
AU - Tetzlaff, Michael T.
AU - Diab, Adi
N1 - Publisher Copyright:
© 2016 The Author(s).
PY - 2016/9/20
Y1 - 2016/9/20
N2 - Background: Immune related adverse events (irAEs) are common side effects of checkpoint inhibitory (CPI) therapies targeting CTLA-4 and PD-1/PD-L1. Grover's disease is an uncommon dermatologic condition with unclear pathogenesis previously reported as an irAE with ipilimumab. Case Presentation: We report an additional case of ipilimumab-induced Grover's disease. Interestingly, this dermatologic side effect did not appear with use of anti-PD-1 therapy in our patient. Immune analysis was performed and suggests a possible role of Th2 cells in its patholgenesis. Conclusion: This case suggests that Grover's disease is an irAE induced by Ipilimumab. Our immune analysis suggests that Th2 cells may be pathogenic mediators which warrants further study.
AB - Background: Immune related adverse events (irAEs) are common side effects of checkpoint inhibitory (CPI) therapies targeting CTLA-4 and PD-1/PD-L1. Grover's disease is an uncommon dermatologic condition with unclear pathogenesis previously reported as an irAE with ipilimumab. Case Presentation: We report an additional case of ipilimumab-induced Grover's disease. Interestingly, this dermatologic side effect did not appear with use of anti-PD-1 therapy in our patient. Immune analysis was performed and suggests a possible role of Th2 cells in its patholgenesis. Conclusion: This case suggests that Grover's disease is an irAE induced by Ipilimumab. Our immune analysis suggests that Th2 cells may be pathogenic mediators which warrants further study.
UR - http://www.scopus.com/inward/record.url?scp=84997712026&partnerID=8YFLogxK
U2 - 10.1186/s40425-016-0157-6
DO - 10.1186/s40425-016-0157-6
M3 - Article
AN - SCOPUS:84997712026
SN - 2051-1426
VL - 4
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
IS - 1
M1 - 55
ER -